文献速递其他结缔组织病

系统性硬化症相关间质性肺病的临床与经济负担

The clinical and economic burden of systemic sclerosis related interstitial lung disease.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

基于澳大利亚硬皮病队列研究2008-2015年数据,链接医疗数据库量化SSc-ILD负担。SSc-ILD患者医疗资源使用更多,人均总费用AUD$48 368 vs AUD$33 657(P<0.001),ILD严重程度和合并PAH是总费用高于中位数的主要决定因素,且患者躯体健康相关生活质量更差。

要点

  • SSc-ILD患者人均总费用AUD$48 368,显著高于无ILD者的AUD$33 657(P<0.001)。
  • ILD严重程度和合并PAH是总费用高于中位数的主要决定因素(OR 5.1,P<0.001;OR 2.6,P=0.01)。
  • SSc-ILD患者躯体HRQoL更差(34.3 vs 39.1,P<0.001),且随ILD严重程度增加而下降(P=0.002)。

核心结论

  • SSc-ILD给医疗系统和患者带来沉重负担,表现为HRQoL差以及医疗资源使用和直接费用增加。

研究设计与样本

  • 澳大利亚硬皮病队列研究中SSc患者临床数据与2008-2015年医疗数据库链接。
  • ILD由高分辨率CT特征性纤维化改变定义,严重程度按HRCT肺受累范围分轻度<10%、中度10-30%、重度>30%。
  • 采用logistic回归估计医疗费用决定因素。

主要发现

  • SSc-ILD患者比无ILD者更多使用住院、急诊和门诊服务,人均总费用AUD$48 368(26 230-93 615)vs AUD$33 657(15 144-66 905),P<0.001。
  • SSc-ILD患者相比无ILD者年均中位超额费用为AUD$1192(807-1212),P<0.001。
  • 重度ILD相比轻度ILD患者年均超额费用为AUD$2321(645-1846),P<0.001。
  • ILD严重程度和合并PAH是总费用高于中位数的主要决定因素(OR 5.1,P<0.001;OR 2.6,P=0.01)。
  • SSc-ILD患者躯体HRQoL较无ILD者差[34.3(10.5)vs 39.1(10.8),P<0.001],且随ILD严重程度增加而进行性下降(P=0.002)。

临床怎么用

  • 临床评估SSc患者时应关注ILD严重程度和合并PAH,因其与更高的医疗费用相关。
  • 对SSc-ILD患者需关注躯体健康相关生活质量,并随ILD严重程度加重而加强管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To quantify the burden of interstitial lung disease (ILD) in SSc. METHODS: Clinical data for SSc patients enrolled in the Australian Scleroderma Cohort Study were linked with healthcare databases for the period 2008-2015. ILD was defined by characteristic fibrotic changes on high-resolution CT (HRCT) lung, while severity was defined by the extent lung involvement on HRCT (mild <10%, moderate 10-30%, severe >30%). Determinants of healthcare cost were estimated using logistic regression. RESULTS: SSc-ILD patients utilized more healthcare resources, including hospitalization, emergency department presentation and ambulatory care services, than those without ILD with a total cost per patient of AUD$48 368 (26 230-93 615) vs AUD$33 657 (15 144-66 905), P<0.001) between 2008-2015. Healthcare utilization was associated with an annual median (25th-75th) excess cost per SSc-ILD patient compared with those without ILD of AUD$1192 (807-1212), P<0.001. Increasing ILD severity was associated with significantly more healthcare utilization and costs with an annual excess cost per patient with severe ILD compared with mild ILD of AUD$2321 (645-1846), P<0.001. ILD severity and the presence of coexistent PAH were the main determinants of overall healthcare cost above median for this SSc-ILD cohort (OR 5.1, P<0.001, and OR 2.6, P=0.01, respectively). Furthermore, SSc-ILD patients reported worse physical HRQoL compared with those without ILD [34.3 (10.5) vs 39.1 (10.8), P<0.001], with a progressive decline with increasing ILD severity (P=0.002). CONCLUSION: SSc-ILD places a large burden on the healthcare system and the patient through poor HRQoL in addition to incremental healthcare resource utilization and associated direct cost.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Morrisroe K, Stevens W, Sahhar J, et al. The clinical and economic burden of systemic sclerosis related interstitial lung disease. Rheumatology (Oxford). 2020. PMID: 31740961. doi:10.1093/rheumatology/kez532

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。